Zeynep Koşaloğlu-Yalçın
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zeynep Koşaloğlu-Yalçın has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
Alessandro Sette
Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla
9 shared publications- Bjoern Peters
Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, California, USA
9 shared publications Bjoern Peters
Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla
6 shared publications- Jason A. Greenbaum
La Jolla Institute for Immunology, La Jolla, USA
6 shared publications - Morten Nielsen
Department of Health Technology, Technical University of Denmark, DK-2800 Lyngby, Denmark
6 shared publications Nina Blazeska
Center for Vaccine Innovation, La Jolla Institute for Immunology , La Jolla, CA 92037
5 shared publications
Latest Publications
- Open Access
- 19 August 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1898826
The Cancer Epitope Database and Analysis Resource (CEDAR): current capabilities and future directions
Cancer epitopes, the molecular structures recognized by T and B cells at the tumor interface, are central to understanding antitumor immunity and developing immunotherapies. Yet despite the rapid growth of cancer immunology data, a comprehensive, continuously updated, and accessible resource for cancer epitope data has been lacking. The Cancer Epitope Database and Analysis Resource (CEDAR, cedar.iedb.org) was established in 2021 to fill this gap, providing curated experimental epitope data alongside a suite of cancer-specific computational tools for epitope prediction and analysis. Built on the validated infrastructure of the Immune Epitope Database (IEDB), CEDAR integrates cancer epitope data with biological, immunological, and clinical context, enabling researchers to explore immune recognition of tumors, identify candidate targets for immunotherapy, and benchmark prediction methods. Here we describe CEDAR’s current capabilities, report on progress in curation, database development, and tool availability, and outline the opportunities and challenges ahead for expanding its scope and utility to the cancer research community.
- 19 August 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1898826
Open AccessThe Cancer Epitope Database and Analysis Resource (CEDAR): current capabilities and future directions
Cancer epitopes, the molecular structures recognized by T and B cells at the tumor interface, are central to understanding antitumor immunity and developing immunotherapies. Yet despite the rapid growth of cancer immunology data, a comprehensive, continuously updated, and accessible resource for cancer epitope data has been lacking. The Cancer Epitope Database and Analysis Resource (CEDAR, cedar.iedb.org) was established in 2021 to fill this gap, providing curated experimental epitope data alongside a suite of cancer-specific computational tools for epitope prediction and analysis. Built on the validated infrastructure of the Immune Epitope Database (IEDB), CEDAR integrates cancer epitope data with biological, immunological, and clinical context, enabling researchers to explore immune recognition of tumors, identify candidate targets for immunotherapy, and benchmark prediction methods. Here we describe CEDAR’s current capabilities, report on progress in curation, database development, and tool availability, and outline the opportunities and challenges ahead for expanding its scope and utility to the cancer research community.
- Open Access
- 12 May 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (W1) , W13-W21
Cancer epitope prediction tools and analysis pipelines in CEDAR
Accurate identification of immunogenic cancer epitopes remains a central challenge in immuno-oncology. The Cancer Epitope Database and Analysis Resource (CEDAR, https://cedar.iedb.org/) was developed to provide comprehensive curation of experimentally validated epitopes and to foster the development of computational tools tailored to the cancer context. Recently, we released a suite of cancer-specific tools and analysis pipelines as part of the https://nextgen-tools.iedb.org/ platform, enabling users to generate, evaluate, and prioritize candidate T cell epitopes in a modular framework. Here, we present the design and functionality of these tools, describe their core methodologies, provide guidance for their use, and illustrate how they can be integrated into end-to-end pipelines. We highlight applications in cancer immunology and personalized immunotherapy by presenting practical use cases.
- 12 May 2026
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (W1) , W13-W21
Open AccessCancer epitope prediction tools and analysis pipelines in CEDAR
Accurate identification of immunogenic cancer epitopes remains a central challenge in immuno-oncology. The Cancer Epitope Database and Analysis Resource (CEDAR, https://cedar.iedb.org/) was developed to provide comprehensive curation of experimentally validated epitopes and to foster the development of computational tools tailored to the cancer context. Recently, we released a suite of cancer-specific tools and analysis pipelines as part of the https://nextgen-tools.iedb.org/ platform, enabling users to generate, evaluate, and prioritize candidate T cell epitopes in a modular framework. Here, we present the design and functionality of these tools, describe their core methodologies, provide guidance for their use, and illustrate how they can be integrated into end-to-end pipelines. We highlight applications in cancer immunology and personalized immunotherapy by presenting practical use cases.
- Open Access
- 6 November 2025
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 74 (12) , 1-17
A meta-analysis of experimentally validated neo-epitopes: patterns, biases, and opportunities
Cancer cells harbor somatic mutations that generate novel amino acid sequences that are absent in the self-proteome. These mutation-derived cancer-specific peptides are defined as “neo-peptides”. Neo-peptides eliciting immune responses, i.e. immunogenic neo-peptides, are defined as “neo-epitopes”. Given their relevance to cancer immunotherapy, we conducted a meta-analysis to examine how experimental evidence informs our understanding of neo-epitopes. Our study is the largest reported to date. Using the cancer epitope database and analysis resource (CEDAR), we analyzed over 16,000 neo-peptides tested in more than 20,000 T cell assays across 180 studies. We found that validated neo-epitope frequencies varied across cancer types, with the highest rates in skin and lung and the lowest in colorectal cancer. Neo-epitopes were enriched in driver genes such as TP53 and KRAS. However, testing frequency correlated with mutation prevalence, revealing bias toward recurrent mutations. Despite the high sequence similarity among RAS family members, validated neo-epitope overlap was minimal, challenging pan-RAS strategies. Shared neo-epitopes across cancer types are rare, with only 16 validated in more than one cancer type. While most assays involved HLA class I, class II alleles presented a higher proportion of validated neo-epitopes. Specific alleles, including HLA-B*40:01 and HLA-DRB1*11:01, were enriched for neo-epitopes, whereas others, like HLA-A*02:01, were enriched for non-immunogenic neo-peptides. Finally, amino acid substitutions that altered hydrophobicity or charge were more common in neo-epitopes. Together, these findings define key features of neo-epitopes, expose methodological and biological biases in the literature, and highlight opportunities to improve the selection and prioritization of neo-epitopes for cancer immunotherapy.
- 6 November 2025
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 74 (12) , 1-17
Open AccessA meta-analysis of experimentally validated neo-epitopes: patterns, biases, and opportunities
Cancer cells harbor somatic mutations that generate novel amino acid sequences that are absent in the self-proteome. These mutation-derived cancer-specific peptides are defined as “neo-peptides”. Neo-peptides eliciting immune responses, i.e. immunogenic neo-peptides, are defined as “neo-epitopes”. Given their relevance to cancer immunotherapy, we conducted a meta-analysis to examine how experimental evidence informs our understanding of neo-epitopes. Our study is the largest reported to date. Using the cancer epitope database and analysis resource (CEDAR), we analyzed over 16,000 neo-peptides tested in more than 20,000 T cell assays across 180 studies. We found that validated neo-epitope frequencies varied across cancer types, with the highest rates in skin and lung and the lowest in colorectal cancer. Neo-epitopes were enriched in driver genes such as TP53 and KRAS. However, testing frequency correlated with mutation prevalence, revealing bias toward recurrent mutations. Despite the high sequence similarity among RAS family members, validated neo-epitope overlap was minimal, challenging pan-RAS strategies. Shared neo-epitopes across cancer types are rare, with only 16 validated in more than one cancer type. While most assays involved HLA class I, class II alleles presented a higher proportion of validated neo-epitopes. Specific alleles, including HLA-B*40:01 and HLA-DRB1*11:01, were enriched for neo-epitopes, whereas others, like HLA-A*02:01, were enriched for non-immunogenic neo-peptides. Finally, amino acid substitutions that altered hydrophobicity or charge were more common in neo-epitopes. Together, these findings define key features of neo-epitopes, expose methodological and biological biases in the literature, and highlight opportunities to improve the selection and prioritization of neo-epitopes for cancer immunotherapy.
- Open Access
- 4 October 2025
- Published by MDPI AG in Preprints.org
Cancer Epitope Prediction Tools & Analysis Pipelines in CEDAR
Accurate identification of immunogenic cancer epitopes remains a central challenge in immuno-oncology. The Cancer Epitope Database and Analysis Resource (CEDAR, cedar.iedb.org) was developed to provide comprehensive curation of experimentally validated epitopes and to foster development of prediction algorithms tailored to the cancer context. Recently, a suite of cancer-specific computational tools was released as part of the Next-Generation IEDB Tools platform (NGT, nextgen-tools.iedb.org/), enabling users to generate, evaluate, and prioritize candidate epitopes in a modular pipeline framework. Here, we present the design and functionality of these tools, describe their core methodologies, provide guidance for their use, and illustrate how they can be integrated into end-to-end pipelines. We highlight key applications in cancer immunology and personalized immunotherapy by presenting practical use cases.
- 4 October 2025
- Published by MDPI AG in Preprints.org
Open AccessCancer Epitope Prediction Tools & Analysis Pipelines in CEDAR
Accurate identification of immunogenic cancer epitopes remains a central challenge in immuno-oncology. The Cancer Epitope Database and Analysis Resource (CEDAR, cedar.iedb.org) was developed to provide comprehensive curation of experimentally validated epitopes and to foster development of prediction algorithms tailored to the cancer context. Recently, a suite of cancer-specific computational tools was released as part of the Next-Generation IEDB Tools platform (NGT, nextgen-tools.iedb.org/), enabling users to generate, evaluate, and prioritize candidate epitopes in a modular pipeline framework. Here, we present the design and functionality of these tools, describe their core methodologies, provide guidance for their use, and illustrate how they can be integrated into end-to-end pipelines. We highlight key applications in cancer immunology and personalized immunotherapy by presenting practical use cases.
- 9 August 2025
- Published by Springer Nature
- Vol. 2932, 75-91
Using the Cancer Epitope Database and Analysis Resource (CEDAR)
The Cancer Epitope Database and Analysis Resource (CEDAR) is a freely accessible catalog of cancer epitope and receptor data linked to the biological, immunological, and clinical contexts in which they were described. CEDAR data is populated by manual curation of the cancer literature and provides a central resource for researchers to access information about cancer antigens and their specific epitopes, which is relevant to our understanding of the role that the immune system plays in cancer progression, prevention, and treatment. In this chapter, we aim to provide a comprehensive overview of the database section of CEDAR. This includes a detailed description of all available query parameters, guidance on navigating through the query results, and a demonstration of how CEDAR can aid cancer research, featuring example research scenarios and queries.
- 9 August 2025
- Published by Springer Nature
- Vol. 2932, 75-91
Using the Cancer Epitope Database and Analysis Resource (CEDAR)
The Cancer Epitope Database and Analysis Resource (CEDAR) is a freely accessible catalog of cancer epitope and receptor data linked to the biological, immunological, and clinical contexts in which they were described. CEDAR data is populated by manual curation of the cancer literature and provides a central resource for researchers to access information about cancer antigens and their specific epitopes, which is relevant to our understanding of the role that the immune system plays in cancer progression, prevention, and treatment. In this chapter, we aim to provide a comprehensive overview of the database section of CEDAR. This includes a detailed description of all available query parameters, guidance on navigating through the query results, and a demonstration of how CEDAR can aid cancer research, featuring example research scenarios and queries.
- Open Access
- 23 May 2024
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52 (W1) , W526-W532
Next-generation IEDB tools: a platform for epitope prediction and analysis
The Next-Generation (NG) IEDB Tools website (https://nextgen-tools.iedb.org) provides users with a redesigned interface to many of the algorithms for epitope prediction and analysis that were originally released on the legacy IEDB Tools website. The initial release focuses on consolidation of all tools related to HLA class I epitopes (MHC binding, elution, immunogenicity, and processing), making all of these predictions accessible from a single application and allowing for their simultaneous execution with minimal user inputs. Additionally, the PEPMatch tool for identifying highly similar epitopes in a set of curated proteomes, as well as a tool for epitope clustering, are available on the site. The NG Tools site allows users to build data pipelines by sending the output of one tool as input for the next. Over the next several years, all pre-existing IEDB Tools, and any newly developed tools, will be integrated into this new site. Here we describe the philosophy behind the redesign and demonstrate the utility and productivity enhancements that are enabled by the new interface.
- 23 May 2024
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52 (W1) , W526-W532
Open AccessNext-generation IEDB tools: a platform for epitope prediction and analysis
The Next-Generation (NG) IEDB Tools website (https://nextgen-tools.iedb.org) provides users with a redesigned interface to many of the algorithms for epitope prediction and analysis that were originally released on the legacy IEDB Tools website. The initial release focuses on consolidation of all tools related to HLA class I epitopes (MHC binding, elution, immunogenicity, and processing), making all of these predictions accessible from a single application and allowing for their simultaneous execution with minimal user inputs. Additionally, the PEPMatch tool for identifying highly similar epitopes in a set of curated proteomes, as well as a tool for epitope clustering, are available on the site. The NG Tools site allows users to build data pipelines by sending the output of one tool as input for the next. Over the next several years, all pre-existing IEDB Tools, and any newly developed tools, will be integrated into this new site. Here we describe the philosophy behind the redesign and demonstrate the utility and productivity enhancements that are enabled by the new interface.
- 28 February 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (736) , eabj9905
A functional identification platform reveals frequent, spontaneous neoantigen-specific T cell responses in patients with cancer
The clinical impact of tumor-specific neoantigens as both immunotherapeutic targets and biomarkers has been impeded by the lack of efficient methods for their identification and validation from routine samples. We have developed a platform that combines bioinformatic analysis of tumor exomes and transcriptional data with functional testing of autologous peripheral blood mononuclear cells (PBMCs) to simultaneously identify and validate neoantigens recognized by naturally primed CD4 + and CD8 + T cell responses across a range of tumor types and mutational burdens. The method features a human leukocyte antigen (HLA)–agnostic bioinformatic algorithm that prioritizes mutations recognized by patient PBMCs at a greater than 40% positive predictive value followed by a short-term in vitro functional assay, which allows interrogation of 50 to 75 expressed mutations from a single 50-ml blood sample. Neoantigens validated by this method include both driver and passenger mutations, and this method identified neoantigens that would not have been otherwise detected using an in silico prediction approach. These findings reveal an efficient approach to systematically validate clinically actionable neoantigens and the T cell receptors that recognize them and demonstrate that patients across a variety of human cancers have a diverse repertoire of neoantigen-specific T cells.
- 28 February 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (736) , eabj9905
A functional identification platform reveals frequent, spontaneous neoantigen-specific T cell responses in patients with cancer
The clinical impact of tumor-specific neoantigens as both immunotherapeutic targets and biomarkers has been impeded by the lack of efficient methods for their identification and validation from routine samples. We have developed a platform that combines bioinformatic analysis of tumor exomes and transcriptional data with functional testing of autologous peripheral blood mononuclear cells (PBMCs) to simultaneously identify and validate neoantigens recognized by naturally primed CD4 + and CD8 + T cell responses across a range of tumor types and mutational burdens. The method features a human leukocyte antigen (HLA)–agnostic bioinformatic algorithm that prioritizes mutations recognized by patient PBMCs at a greater than 40% positive predictive value followed by a short-term in vitro functional assay, which allows interrogation of 50 to 75 expressed mutations from a single 50-ml blood sample. Neoantigens validated by this method include both driver and passenger mutations, and this method identified neoantigens that would not have been otherwise detected using an in silico prediction approach. These findings reveal an efficient approach to systematically validate clinically actionable neoantigens and the T cell receptors that recognize them and demonstrate that patients across a variety of human cancers have a diverse repertoire of neoantigen-specific T cells.
- Open Access
- 9 January 2024
- Published by Oxford University Press (OUP) in NAR Cancer
- Vol. 6 (1) , zcae002
A large-scale study of peptide features defining immunogenicity of cancer neo-epitopes
Accurate prediction of immunogenicity for neo-epitopes arising from a cancer associated mutation is a crucial step in many bioinformatics pipelines that predict outcome of checkpoint blockade treatments or that aim to design personalised cancer immunotherapies and vaccines. In this study, we performed a comprehensive analysis of peptide features relevant for prediction of immunogenicity using the Cancer Epitope Database and Analysis Resource (CEDAR), a curated database of cancer epitopes with experimentally validated immunogenicity annotations from peer-reviewed publications. The developed model, ICERFIRE (ICore-based Ensemble Random Forest for neo-epitope Immunogenicity pREdiction), extracts the predicted ICORE from the full neo-epitope as input, i.e. the nested peptide with the highest predicted major histocompatibility complex (MHC) binding potential combined with its predicted likelihood of antigen presentation (%Rank). Key additional features integrated into the model include assessment of the BLOSUM mutation score of the neo-epitope, and antigen expression levels of the wild-type counterpart which is often reflecting a neo-epitope's abundance. We demonstrate improved and robust performance of ICERFIRE over existing immunogenicity and epitope prediction models, both in cross-validation and on external validation datasets.
- 9 January 2024
- Published by Oxford University Press (OUP) in NAR Cancer
- Vol. 6 (1) , zcae002
Open AccessA large-scale study of peptide features defining immunogenicity of cancer neo-epitopes
Accurate prediction of immunogenicity for neo-epitopes arising from a cancer associated mutation is a crucial step in many bioinformatics pipelines that predict outcome of checkpoint blockade treatments or that aim to design personalised cancer immunotherapies and vaccines. In this study, we performed a comprehensive analysis of peptide features relevant for prediction of immunogenicity using the Cancer Epitope Database and Analysis Resource (CEDAR), a curated database of cancer epitopes with experimentally validated immunogenicity annotations from peer-reviewed publications. The developed model, ICERFIRE (ICore-based Ensemble Random Forest for neo-epitope Immunogenicity pREdiction), extracts the predicted ICORE from the full neo-epitope as input, i.e. the nested peptide with the highest predicted major histocompatibility complex (MHC) binding potential combined with its predicted likelihood of antigen presentation (%Rank). Key additional features integrated into the model include assessment of the BLOSUM mutation score of the neo-epitope, and antigen expression levels of the wild-type counterpart which is often reflecting a neo-epitope's abundance. We demonstrate improved and robust performance of ICERFIRE over existing immunogenicity and epitope prediction models, both in cross-validation and on external validation datasets.
- Open Access
- 12 January 2023
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 14, 1082168
Estimating tissue-specific peptide abundance from public RNA-Seq data
Several novel MHC class I epitope prediction tools additionally incorporate the abundance levels of the peptides’ source antigens and have shown improved performance for predicting immunogenicity. Such tools require the user to input the MHC alleles and peptide sequences of interest, as well as the abundance levels of the peptides’ source proteins. However, such expression data is often not directly available to users, and retrieving the expression level of a peptide’s source antigen from public databases is not trivial. We have developed the Peptide eXpression annotator (pepX), which takes a peptide as input, identifies from which proteins the peptide can be derived, and returns an estimate of the expression level of those source proteins from selected public databases. We have also investigated how the abundance level of a peptide can be best estimated in cases when it can originate from multiple transcripts and proteins and found that summing up transcript-level expression values performs best in distinguishing ligands from decoy peptides.
- 12 January 2023
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 14, 1082168
Open AccessEstimating tissue-specific peptide abundance from public RNA-Seq data
Several novel MHC class I epitope prediction tools additionally incorporate the abundance levels of the peptides’ source antigens and have shown improved performance for predicting immunogenicity. Such tools require the user to input the MHC alleles and peptide sequences of interest, as well as the abundance levels of the peptides’ source proteins. However, such expression data is often not directly available to users, and retrieving the expression level of a peptide’s source antigen from public databases is not trivial. We have developed the Peptide eXpression annotator (pepX), which takes a peptide as input, identifies from which proteins the peptide can be derived, and returns an estimate of the expression level of those source proteins from selected public databases. We have also investigated how the abundance level of a peptide can be best estimated in cases when it can originate from multiple transcripts and proteins and found that summing up transcript-level expression values performs best in distinguishing ligands from decoy peptides.
- Open Access
- 17 October 2022
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 51 (D1) , D845-D852
The Cancer Epitope Database and Analysis Resource (CEDAR)
We established The Cancer Epitope Database and Analysis Resource (CEDAR) to catalog all epitope data in the context of cancer. The specific molecular targets of adaptive T cell and B cell immune responses are referred to as epitopes. Epitopes derived from cancer antigens are of high relevance as they are recognized by anti-cancer immune cells. Detailed knowledge of the molecular characteristic of cancer epitopes and associated metadata is relevant to understanding and planning prophylactic and therapeutic applications and accurately characterizing naturally occurring immune responses and cancer immunopathology. CEDAR provides a freely accessible, comprehensive collection of cancer epitope and receptor data curated from the literature and serves as a companion site to the Immune Epitope Database (IEDB), which is focused on infectious, autoimmune, and allergic diseases. CEDAR is freely accessible at https://cedar.iedb.org/.
- 17 October 2022
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 51 (D1) , D845-D852
Open AccessThe Cancer Epitope Database and Analysis Resource (CEDAR)
We established The Cancer Epitope Database and Analysis Resource (CEDAR) to catalog all epitope data in the context of cancer. The specific molecular targets of adaptive T cell and B cell immune responses are referred to as epitopes. Epitopes derived from cancer antigens are of high relevance as they are recognized by anti-cancer immune cells. Detailed knowledge of the molecular characteristic of cancer epitopes and associated metadata is relevant to understanding and planning prophylactic and therapeutic applications and accurately characterizing naturally occurring immune responses and cancer immunopathology. CEDAR provides a freely accessible, comprehensive collection of cancer epitope and receptor data curated from the literature and serves as a companion site to the Immune Epitope Database (IEDB), which is focused on infectious, autoimmune, and allergic diseases. CEDAR is freely accessible at https://cedar.iedb.org/.